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We report a 62-yr-old man with severe jaundice and
weight loss attrihuted to methyltestosterone administra-
tion. This case is unusual hoth in the severity of the
cholestasis as well as the associated findings that mim-
icked an underlying malignancy.
INTRODUCTION
Drug-induced hepatic toxicity is characterized by
either hepatocellular necrosis, choleslasis. or a mixed
disorder. Whereas cholestasis is a well-recognized com-
plication of estrogen therapy and forms part ofa clinical
spectrum which includes intrahepatic cholestasis of
pregnancy (1), cholestasis complicating androgenic ste-
roid use appears to be less common (2). Indeed, recent
reports have emphasized its rarity and benignity (3, 4).
We present a case of severe cholestasis attributed to
methyltestosterone (MT) and discuss potential patho-
genic mechanisms.
CASE REPORT
A 62-yr-old man was self-referred for evaluation of
jaundice and weight loss. He had been well 6 wk earlier
when he developed lassitude, anorexia, nausea, dark
urine, and acholic stools. Jaundice became apparent
3 wk later and he developed severe pruritus. There was
no abdominal pain, arthralgia or myalgia, hematemesis,
or melena. His weight had decreased by 23 lb in 6 wk.
He had never received intravenous drugs or blood
products. For 9 months before presentation he took 10
mg MT po daily with the intention of increasing sexual
potency. He took no other medications. He had con-
sumed alcohol daily for many years until 1972, after
which he rarely drank. There was no personal or family
history of gastrointestinal or liver disease.
On presentation he was icteric and there were excor-
iations on his skin. His liver was enlarged (14 cm span)
and nontender. There were no signs of encephalopathy,
splenomegaly, spider angiomata, or ascites, and all
other systems were normal. Peak serum bilirubin was
29.3 mg/dl, alkaline phosphatase 290 IU, and GOT
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243 U. Serum tota! protein, albumin and creatinine,
Hb, white cell count, blood glucose, and prothrombin
lime were normal. The erythrocyte sedimentation rate
was 89 mm/h. HBsAg, anti-HBsAg, and anti-HA Ag
{IgM) were negative. Abdominal sonography showed
cholelithiasis without biliary tract dilatation. Similarly,
endoscopic retrograde cholangiography showed multi-
ple gallstones with normal caliber intra- and extrahe-
patic bile ducts. There were no stones present in the
common bile duct. The pancreatic duct was normal. A
percutaneous liver biopsy showed severe cholestasis
with precipitated bile in many bile canaliculi (Figure
I). There was only a minimal associated inflammatory
reaction and neocholangiogenesis was present in occa-
sional portal tracts.
MT was discontinued and the patient made a gradual
recovery and was asymptomatic 2 months later, having
gained 11 lb. His laboratory tests at that time were as
follows: serum bilirubin 1.2 mg/100 ml, alkaline phos-
phatase 104 IU, SGOT 29 U, albumin 4.5 g/di, and
erythrocyte sedimentation rate 31 mm/h. He remains
well 9 months after stopping MT.
DISCUSSION
Oral MT was first administered in 1939 and by 1959,
as summarized by Foss and Simpson (2), there had
been 42 reports in the literature of cholestatic jaundice
in patienis receiving oral MT. The duration of tberapy
before the onset of jaundice ranged from 8 days to 12
months, with a median of 3 months. The highest re-
corded serum bilirubin was 34 mg/100 ml. Anorexia,
nausea, and lethargy were common features. The daily
dose of MT varied from 10 to 100 mg and did not
appear to correlate with the latent period before the
onset of jaundice. Jaundice resolved on stopping MT
in all but one patient. The median duration of jaundice
after stopping MT was 2 months with a range of 9 days
to 10 months. One patient, who received 30 mg MT
daily for 6 wk as an anabolic agent after an abdominal-
perineal resection for carcinoma ofthe rectum, died 2
months after the onset of jaundice. Subsequent reports,
however, have stressed the rarity of this syndrome (3,
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FIG. I. Percutaneous liver biopsy demonstrating precipitated bile
in many bile canaliculi and a mild inflammatory reaction involving
the portal triad (hematoxylin and eosin, x200).
4). Indeed, Westaby et ai (4) described 60 individuals
(42 female transexuals and 18 impotent males) who
received 150 mg MT daily for up to 5 yr, 46 of whom
received MT for 6 months or more. Mild disturbances
of liver biochemistry tests occurred in 19, but in only
one person was serum bilirubin elevated (2.9 nmol/1)
(4).
The present case has many features typical of MT-
induced cholestasis. The duration of therapy before
jaundice, tbe degree of jaundice, the duration of jaun-
dice, and its resolution after stopping MT all are in
accord with the description of Foss and Simpson (2).
The severity of weight loss and elevated sedimentation
rate in the present case mimicked carcinoma of the
pancreas, thus necessitating the detailed investigations,
all of which were negative.
The mechanisms by which MT induces cholestasis
are uncertain, perhaps because estrogen-induced jaun-
dice is a more common clinical problem and has re-
ceived greater attention. Many disturbances of hepatic
function have been ascribed to the use ofthe structur-
ally related estrogens in vivo and in vitro (1). These
include reduction in bile salt-independent bile flow (5),
reduced (Na*,K*) ATPase activity and fluidity of liver
plasma membranes (6), and altered morphology of
hepatocyte tight junctions with increased blood to bile
permeability (7). It is probable that these abnormalities
are interrelated since the administration ofthe nonionic
detergent Triton WR 1339 (8) and the methyl donor,
S-adenosyl-L-methionine (9) to rats with ethinyl estra-
diol-induced bile sectretory failure restores to normal
not only bile salt-independent bile flow, but also mem-
brane (Na*.,K"̂ ) ATPase activity, and membrane fluid-
ity. None of these proposed mechanisms fully account
for the wide differences in individual susceptibility to
estrogen-induced cholestasis. bul it is of note that
administration of S-adenosyl-L-methionine was re-
cently shown to be effective in the treatment of intra-
hepatic cholestasis of pregnancy (10).
It is not known whether there are similar disturbances
in hepatocyte function in MT-induced choleslasis.
However, studies both in a perfused rat liver model and
in isolated rat hepatocytes have demonstrated that no-
rethandrolone, a 17«-alkyiated anabolic steroid, results
in a loss of pericanalicular microfilaments (11). Thus it
is likely that MT-induced cholestasis is also a complex
phenomenon involving alteration in hepatocyte struc-
ture and function. An explanation for the relative rarity
of a severe cholestatic picture such as that presented
herein will have to await further study.
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